How to Get Evenity (Romosozumab) in Kansas

What Is Romosozumab and Why Does It Matter for Osteoporosis?

Romosozumab is a monoclonal antibody that inhibits sclerostin, a protein produced by osteocytes that suppresses bone formation. By blocking sclerostin, romosozumab does something no bisphosphonate can: it simultaneously increases bone formation and decreases bone resorption. The FDA approved Evenity in April 2019 for postmenopausal women at high risk of fracture [1].

A Dual-Action Mechanism

Most osteoporosis drugs work on one side of the equation. Bisphosphonates like alendronate slow breakdown. Teriparatide (Forteo) stimulates building. Romosozumab acts on both pathways at once, producing rapid gains in bone mineral density (BMD) within the first 6 to 12 months of treatment [2].

The ARCH Trial Results

In the ARCH trial (N=4,093), romosozumab followed by alendronate reduced new vertebral fractures by 48% compared with alendronate alone over 24 months [3]. The study also showed a 27% lower risk of clinical fractures in the romosozumab-to-alendronate sequence. These numbers drove the drug's positioning as a first-line option for patients with very high fracture risk, defined by the Endocrine Society as those with a T-score ≤ −2.5 plus a prior fragility fracture [4].

Who Is a Candidate?

The FDA-approved label restricts Evenity to postmenopausal women at high fracture risk. Off-label prescribing for men with osteoporosis or glucocorticoid-induced bone loss does occur, though insurance coverage for these populations is inconsistent. The boxed warning contraindicates use in patients who have had a myocardial infarction or stroke within the preceding 12 months [1].

Kansas Prescribing Rules for Evenity

Kansas permits licensed physicians (MDs and DOs), advanced practice registered nurses (APRNs), and physician assistants (PAs) to prescribe Evenity. Each prescriber category has specific scope-of-practice conditions that affect how quickly a patient can start treatment.

MD and DO Prescribers

Any Kansas-licensed physician can prescribe romosozumab. Endocrinologists, rheumatologists, and geriatricians write the majority of Evenity prescriptions. Some primary care physicians prescribe it for established patients with confirmed high-risk osteoporosis, though many prefer to refer out given the specialty pharmacy logistics and prior authorization burden.

APRN and PA Prescribers

Kansas APRNs hold full prescriptive authority when they maintain a collaborative practice agreement. PAs prescribe under physician supervision. Both can initiate Evenity, order the prerequisite DEXA scan, and complete prior authorization paperwork. In rural Kansas counties where endocrinology access is limited, APRNs often serve as the primary osteoporosis prescriber [5].

Telehealth Prescribing

The Kansas Board of Healing Arts allows telehealth prescribing for Evenity. A provider licensed in Kansas can evaluate a patient via synchronous video visit, review existing imaging and labs, and submit a prescription to a specialty pharmacy. The provider does not need a physical office in Kansas, but they must hold an active Kansas medical license. This opens access for patients in western Kansas who may live hours from the nearest bone-health specialist.

Lab Work and Screening Before Starting Evenity

No prescriber should write an Evenity prescription without recent bone density imaging and a cardiovascular risk assessment. The FDA boxed warning and most insurer prior authorization forms mandate specific documentation.

Required DEXA Scan

A dual-energy X-ray absorptiometry (DEXA) scan confirming a T-score of −2.5 or lower at the lumbar spine, femoral neck, or total hip is the baseline requirement. Most insurers want a scan performed within the past 24 months. If the patient has never had a DEXA, Medicare covers screening for women aged 65 and older, and for younger postmenopausal women with clinical risk factors [6].

Cardiovascular Risk Evaluation

The FDA boxed warning states that romosozumab may increase the risk of myocardial infarction, stroke, and cardiovascular death [1]. Before prescribing, clinicians should assess:

• History of MI or stroke (absolute contraindication within the prior 12 months)
• Blood pressure (uncontrolled hypertension should be treated first)
• 10-year ASCVD risk score using the ACC/AHA Pooled Cohort Equations
• Lipid panel and HbA1c if not recently checked

The American Association of Clinical Endocrinology (AACE) 2020 guidelines recommend that "romosozumab should be reserved for patients whose fracture risk substantially outweighs the potential cardiovascular risk" [7].

Baseline Blood Work

Standard pre-treatment labs include serum calcium, 25-hydroxyvitamin D, and a comprehensive metabolic panel. Hypocalcemia must be corrected before starting Evenity. Vitamin D levels below 30 ng/mL should be repleted with ergocalciferol or cholecalciferol supplementation for 8 to 12 weeks prior to the first injection [4].

Insurance Coverage and Prior Authorization in Kansas

Getting an Evenity prescription is only half the challenge. The prior authorization process in Kansas varies by payer, and one major payer, Kansas Medicaid, does not cover it for osteoporosis at all.

Kansas Medicaid

Kansas Medicaid does not list romosozumab on its preferred drug list for osteoporosis. Coverage is restricted to type 2 diabetes indications, which does not apply to Evenity's FDA-approved use. Patients on Medicaid in Kansas who need romosozumab must pursue alternatives: Amgen's patient assistance program (Amgen Assist 360), clinical trials, or out-of-pocket payment.

Medicare Part B

Evenity is covered under Medicare Part B as a physician-administered injectable. The drug is given as two subcutaneous injections of 105 mg each (totaling 210 mg) during a single office visit. Medicare typically requires prior authorization documentation including the DEXA T-score, fracture history, documentation of bisphosphonate inadequacy or intolerance, and cardiovascular clearance. Out-of-pocket costs under Part B depend on the patient's supplemental coverage but often run $300 to $500 per dose after the 20% coinsurance [8].

Commercial Insurance

Most major commercial plans in Kansas (Blue Cross Blue Shield of Kansas, Aetna, UnitedHealthcare, Cigna) cover Evenity with prior authorization. Common criteria include:

• Postmenopausal status
• DEXA T-score ≤ −2.5
• Prior fragility fracture or FRAX score above the intervention threshold
• Trial and failure of, or contraindication to, at least one bisphosphonate
• No MI or stroke within 12 months

Approval timelines range from 3 to 14 business days. Denials can be appealed with a peer-to-peer review. The Endocrine Society's position statement on romosozumab access notes that "step therapy requirements may delay treatment for patients at imminent fracture risk" [4].

Amgen Assist 360

Amgen's patient support program helps with copay assistance for commercially insured patients (reducing out-of-pocket costs to as low as $5 per dose) and provides free drug for uninsured or underinsured patients who meet income criteria. Kansas residents can enroll by calling 1-844-EVENITY or through the Amgen website [9].

Finding a Prescriber in Kansas

Access to romosozumab varies significantly between urban and rural parts of the state. Kansas City, Wichita, and Topeka have concentrations of endocrinologists and rheumatologists. The western two-thirds of the state has far fewer specialists.

In-Person Specialists

The University of Kansas Health System in Kansas City operates the largest academic endocrinology practice in the state. Ascension Via Christi in Wichita and Stormont Vail Health in Topeka also have bone-health programs. Patients in these metro areas can typically get a new-patient endocrinology appointment within 4 to 8 weeks.

Telehealth Pathways

For patients in rural counties, telehealth eliminates the distance barrier. A licensed Kansas provider can conduct a video consultation, review a DEXA scan performed at a local imaging center, check labs drawn at a nearby draw site, and prescribe Evenity to be shipped from a specialty pharmacy directly to the patient's home or local infusion center. The injection is subcutaneous (not intravenous), so it can be administered in a primary care office, an infusion suite, or even self-administered after training.

Wait Times and Timeline

From initial consultation to first injection, expect 3 to 6 weeks in a best-case scenario. That timeline breaks down roughly as follows:

• Week 1: Telehealth or in-person evaluation, lab orders placed
• Week 2: DEXA scan and blood draw completed
• Week 3: Results reviewed, prior authorization submitted
• Weeks 3 to 5: Prior authorization processed (3 to 14 business days)
• Week 5 to 6: Specialty pharmacy ships drug, first injection scheduled

Delays happen most often at the prior authorization step. Denials add 2 to 4 weeks for appeals.

Pharmacy Access and Administration in Kansas

Evenity is not stocked at retail pharmacies. It requires specialty pharmacy dispensing due to cold-chain storage requirements and its high cost.

Specialty Pharmacies Serving Kansas

National specialty pharmacies that ship to Kansas include Accredo (Express Scripts), OptumRx Specialty, CVS Specialty, and BioPlus. Some Kansas-based specialty pharmacies also dispense romosozumab. The drug ships in insulated packaging with temperature monitors and typically arrives within 1 to 3 business days after prior authorization approval.

503A Compounding Pharmacies

Kansas licenses 503A compounding pharmacies, but romosozumab is a biologic monoclonal antibody that cannot be compounded. There is no generic or biosimilar version available as of May 2026. Any pharmacy claiming to compound romosozumab should be reported to the Kansas State Board of Pharmacy [10].

Administration Details

Each monthly dose consists of two prefilled syringes, each containing 105 mg/1.17 mL. Both injections are given during a single visit. The injection sites are the abdomen, thigh, or upper arm. Patients rotate sites each month. The full course lasts 12 months (12 doses), after which patients transition to an antiresorptive agent such as alendronate or denosumab to maintain BMD gains [3].

Cardiovascular Safety: What Kansas Patients Should Know

The boxed warning on Evenity is the single biggest factor that slows or prevents prescribing. Understanding the data helps patients and providers make informed decisions.

What the ARCH Trial Showed

In the ARCH trial, the romosozumab group had a higher rate of adjudicated serious cardiovascular events compared with the alendronate group: 2.5% vs. 1.9% over 12 months of active treatment [3]. The absolute difference was 0.6 percentage points. The FRAME trial (N=7,180), which compared romosozumab to placebo, did not show a statistically significant increase in cardiovascular events [11].

Clinical Interpretation

The discrepancy between ARCH and FRAME has generated debate. One hypothesis is that alendronate may have a mild cardioprotective effect, making the comparator arm in ARCH look safer rather than romosozumab looking more dangerous. The Endocrine Society and AACE both recommend individual cardiovascular risk assessment rather than blanket avoidance [4][7].

Practical Screening Steps

Before initiating Evenity, Kansas providers should document:

• No MI or stroke in the past 12 months
• Blood pressure at or below 140/90 mmHg (or actively treated)
• A shared decision-making conversation about the cardiovascular signal
• The patient's 10-year ASCVD risk score

Patients with a 10-year ASCVD risk above 20% may be better served by denosumab or teriparatide as alternatives, depending on their fracture risk profile.

Cost and Financial Assistance

The wholesale acquisition cost (WAC) for a single Evenity dose is approximately $1,825 per month. A full 12-month course runs roughly $22,000 to $26,000 before insurance [9].

Reducing Out-of-Pocket Costs

Several pathways exist for Kansas patients:

• Amgen Assist 360 copay card: Reduces commercial insurance copays to as low as $5/month
• Medicare patients: Supplemental Medigap or Medicare Advantage plans may cover the 20% Part B coinsurance
• Uninsured patients: Amgen's patient assistance program provides free Evenity to qualifying patients with household income at or below 300% of the federal poverty level
• State pharmaceutical assistance: Kansas does not operate a state pharmaceutical assistance program for osteoporosis drugs, but the Kansas Department for Aging and Disability Services can connect patients with federal resources

Comparing Costs to Alternatives

Denosumab (Prolia) costs approximately $1,600 to $1,800 per dose given every 6 months. Teriparatide (Forteo) runs $3,200 to $3,800 per month for a 24-month course. Bisphosphonates like generic alendronate cost under $20/month. The cost-per-quality-adjusted-life-year analysis in a 2020 study published in the Journal of Bone and Mineral Research found romosozumab-to-alendronate sequencing cost-effective at a $150,000/QALY threshold for women aged 70+ with a T-score ≤ −3.0 and prior vertebral fracture [12].

After the 12-Month Course: What Comes Next

Romosozumab is not a lifelong therapy. The 12-dose course is finite by design.

Transition to Antiresorptive Therapy

Bone density gains from romosozumab begin to reverse within 12 months of stopping if no follow-on therapy is prescribed. The ARCH trial protocol transitioned all patients to alendronate 70 mg weekly after completing romosozumab [3]. Denosumab is the other common sequencing option, particularly for patients who cannot tolerate oral bisphosphonates.

Monitoring After Completion

A follow-up DEXA scan 12 months after completing romosozumab confirms the BMD response. Typical gains range from 13% to 15% at the lumbar spine and 5% to 7% at the total hip over the 12-month treatment period [2]. Patients should continue calcium (1,000 to 1,200 mg/day) and vitamin D (800 to 1,000 IU/day) supplementation indefinitely, per the National Osteoporosis Foundation recommendations [6].